TY - JOUR
T1 - Identification of hydrallazine and hydrallazine hydrazone metabolites in human body fluids and quantitative in vitro comparisons of their smooth muscle relaxant activity.
AU - Haegele, KD
AU - McLean, AJ
AU - du Souich, P.
AU - Barron, K.
AU - Laquer, J.
AU - McNay, JL
AU - Carrier, O.
PY - 1978/6
Y1 - 1978/6
N2 - 1 Serum and urine from hypertensive subjects on chronic oral hydrallazine therapy were studied using gas chromatographic/mass spectrometry techniques. 2 Metabolites resulting from acetylation, hydrolysis and conjugation reactions were detected. The acetone, pyruvate and alpha‐ketoglutarate hydrazone were identified. 3 The activity of the pyruvate and alpha‐ketoglutarate hydrazones were compared with that of hydrallazine using isolated rabbit aortic strips. 4 Both hydrazones were active under in vitro conditions, producing smooth muscle relaxant effects equal to those of hydrallazine. 5 It is concluded that hydrazone metabolites will contribute to the hypotensive effects of hydrallazine therapy in proportion to their relative abundance, persistence in vascular tissues and intrinsic activity. 1978 The British Pharmacological Society
AB - 1 Serum and urine from hypertensive subjects on chronic oral hydrallazine therapy were studied using gas chromatographic/mass spectrometry techniques. 2 Metabolites resulting from acetylation, hydrolysis and conjugation reactions were detected. The acetone, pyruvate and alpha‐ketoglutarate hydrazone were identified. 3 The activity of the pyruvate and alpha‐ketoglutarate hydrazones were compared with that of hydrallazine using isolated rabbit aortic strips. 4 Both hydrazones were active under in vitro conditions, producing smooth muscle relaxant effects equal to those of hydrallazine. 5 It is concluded that hydrazone metabolites will contribute to the hypotensive effects of hydrallazine therapy in proportion to their relative abundance, persistence in vascular tissues and intrinsic activity. 1978 The British Pharmacological Society
UR - http://www.scopus.com/inward/record.url?scp=0017891842&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2125.1978.tb01662.x
DO - 10.1111/j.1365-2125.1978.tb01662.x
M3 - Article
C2 - 656292
AN - SCOPUS:0017891842
SN - 0306-5251
VL - 5
SP - 489
EP - 494
JO - British Journal of Clinical Pharmacology
JF - British Journal of Clinical Pharmacology
IS - 6
ER -